3 completed, 3 terminated, 2 recruiting, 1 not yet recruiting. 6 Phase 2, 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 2, Terminated 2, Not yet recruiting 1, Recruiting 1 |
| Phase 1 | 4 | Recruiting 2, Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow ImmunoGenesis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer Evofosfamide - Castration Resistant Prostate Cancer | Phase 2 | Not yet recruiting | University Health Network, Toronto | 35 | 2026-10-01 | 2026-09-24 |
| A Study of Evofosfamide in Combination with Zalifrelimab and Balstilimab Evofosfamide, Zalifrelimab, Balstilimab - Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | ImmunoGenesis | 71 | 2025-01-08 | 2025-01-21 |
| Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors IMGS-001 - Solid Tumor | Phase 1 | Recruiting | ImmunoGenesis | 105 | 2023-09-07 | 2026-09-04 |
| Study of TH-302 or Placebo in Combination With Pemetrexed in Patients With Non-squamous Non-small Cell Lung Cancer TH-302 combination with pemetrexed, Matched placebo in combination with pemetrexed - Non-small Cell Lung Cancer | Phase 2 | Terminated | ImmunoGenesis | 265 | 2014-06-01 | 2025-05-16 |
| Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer TH-302, Nab-paclitaxel, Gemcitabine - Pancreatic Cancer | Phase 1 | Terminated | ImmunoGenesis | 19 | 2014-01-01 | 2025-05-11 |
| A Phase 2 Biomarker - Enriched Study of TH-302 in Subjects With Advanced Melanoma TH-302 - Metastatic Melanoma | Phase 2 | Terminated | ImmunoGenesis | 11 | 2013-05-01 | 2025-05-11 |
| Clinical Trial Testing TH-302 in Combination With Gemcitabine in Previously Untreated Subjects With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma TH-302, Gemcitabine, Placebo (5 percent dextrose - D5W) - Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma | Phase 3 | Completed | ImmunoGenesis | 693 | 2012-12-01 | 2025-05-11 |
| Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Gemzar (Gemcitabine), TH-302 - Pancreatic Adenocarcinoma | Phase 2 | Completed | ImmunoGenesis | 214 | 2010-06-01 | 2025-05-11 |
| Dose-Escalation Study of TH-302 in Combination With Doxorubicin to Treat Patients With Advanced Soft Tissue Sarcoma TH-302 - Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | ImmunoGenesis | 107 | 2008-08-01 | 2025-05-13 |
Pancreatic Neoplasms (3) · Neoplasm Metastasis (2) · Carcinoma, Non-Small-Cell Lung (1) · Lung Neoplasms (1) · Melanoma (1) · Prostatic Neoplasms (1) · Sarcoma (1) · Squamous Cell Carcinoma of Head and Neck (1)
TH 302 (7) · Gemcitabine (3) · 130-nm albumin-bound paclitaxel (1) · Pemetrexed (1) · balstilimab (1)
United States (8) · Canada (2) · Germany (2) · Czechia (1) · Greece (1) · Hungary (1) · Italy (1) · Poland (1) · Romania (1) · Russia (1) · Spain (1)
Tillman Pearce, MD (2) · Antonio Gualberto, MD, PhD (1) · Jonathan Goldman, MD (1) · Kristen Ganjoo, MD (1) · Mitesh Borad, MD (1) · Shantan Reddy, MD (1)